blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP4081240

EP4081240 - COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  30.09.2022
Database last updated on 01.10.2024
FormerThe international publication has been made
Status updated on  11.06.2021
Most recent event   Tooltip28.05.2024Amendment by applicant 
Applicant(s)For all designated states
Acceleron Pharma Inc.
128 Sidney Street
Cambridge, MA 02139 / US
[2022/44]
Inventor(s)01 / LI, Gang
39 Dawson Drive
Sudbury, MA 01776 / US
02 / KUMAR, Ravindra
421 Arlington Street
Acton, MA 01720 / US
 [2022/44]
Representative(s)Vossius & Partner Patentanwälte Rechtsanwälte mbB
Siebertstraße 3
81675 München / DE
[2022/44]
Application number, filing date20897464.203.12.2020
[2022/44]
WO2020US63160
Priority number, dateUS201962943013P03.12.2019         Original published format: US 201962943013 P
[2022/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2021113544
Date:10.06.2021
Language:EN
[2021/23]
Type: A1 Application with search report 
No.:EP4081240
Date:02.11.2022
Language:EN
The application published by WIPO in one of the EPO official languages on 10.06.2021 takes the place of the publication of the European patent application.
[2022/44]
Search report(s)International search report - published on:AU10.06.2021
(Supplementary) European search report - dispatched on:EP07.11.2023
ClassificationIPC:A61K38/18, C07K14/51, C07K14/71, A61K39/395, A61K47/68, A61K31/7088, A61P9/12, A61P11/00, A61K38/17, A61K45/06
[2023/49]
CPC:
A61P9/12 (EP,AU,US); A61K38/179 (EP,AU,US); A61K38/177 (EP);
A61K38/1796 (EP); A61K38/1875 (EP,AU); A61K45/06 (EP);
A61P11/00 (EP,AU); C07K2319/30 (EP,AU) (-)
Former IPC [2022/44]A61K38/18, C07K14/51, C07K14/71, A61K39/395, A61K47/68, A61K31/7088, A61P9/12, A61P11/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2022/44]
TitleGerman:ZUSAMMENSETZUNGEN UND VERFAHREN ZUM BEHANDELN VON PULMONALER HYPERTONIE[2022/44]
English:COMPOSITIONS AND METHODS FOR TREATING PULMONARY HYPERTENSION[2022/44]
French:COMPOSITIONS ET MÉTHODES DE TRAITEMENT DE L'HYPERTENSION PULMONAIRE[2022/44]
Entry into regional phase30.06.2022National basic fee paid 
30.06.2022Search fee paid 
30.06.2022Designation fee(s) paid 
30.06.2022Examination fee paid 
Examination procedure30.06.2022Examination requested  [2022/44]
23.05.2024Amendment by applicant (claims and/or description)
23.05.2024Date on which the examining division has become responsible
Fees paidRenewal fee
09.12.2022Renewal fee patent year 03
12.12.2023Renewal fee patent year 04
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]WO2017149306  (CAMBRIDGE ENTPR LTD [GB]) [Y] 1-14 * page 2, line 32 - page 3, line 4; claims 1-23 *;
 [Y]  - HE JIANG ET AL, "The Prodomain-bound Form of Bone Morphogenetic Protein 10 Is Biologically Active on Endothelial Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, US, (20160205), vol. 291, no. 6, doi:10.1074/jbc.M115.683292, ISSN 0021-9258, pages 2954 - 2966, XP055684048 [Y] 1-14 * page 2955, column 1, paragraph 4 - column 2, paragraph 3 * * page 2964, column 2, paragraph 3 - page 2956, column 1, paragraph 1 *

DOI:   http://dx.doi.org/10.1074/jbc.M115.683292
International search[X]WO2010128158  (NOVARTIS AG [CH], et al) [X] 2-3 * Abstract, page 2 para. 3, page 11 para. 2 *;
 [X]WO2012145539  (ACCELERON PHARMA INC [US], et al) [X] 2-3, 17-20, 24-26, 45 * page 40 para. 1, page 52 lines 30-31, page 53 lines 14-15, Figure 13, pages 21-22, SEQ ID NOs: 36, 35, 34, 33 *;
 [X]WO2016005756  (CAMBRIDGE ENTPR LTD [GB]) [X] 1-4,21-23 * page 9 lines 9-11, page 24 lines 31-36, page 25 lines 1-8, claims 3, 9, SEQ ID NO: 2 in Sequence Listing *;
 [X]WO2016054406  (BRIGHAM & WOMENS HOSPITAL [US], et al) [X] 1-4, 9-10 * page 35, Examples *;
 [X]US2017137503  (SEEHRA JASBIR [US], et al) [X] 2-3, 15-16, 24-26, 44 * Examples 1-2, 12, 13, SEQ ID NOs: 5 and 3 in the Sequence Listing *;
 [X]WO2017176938  (ACCELERON PHARMA INC [US]) [X] 2-3, 13-14, 24-26, 43 * Abstract, page 3 para. 3, page 5 para.2, pages 59-61, SEQ ID NOs: 14 and 16 *;
 [X]WO2018013936  (ACCELERON PHARMA INC [US]) [X] 1-4, 27-42 * Example 1, in particular page 151 para. 3, Examples 14-15, page 7 lines 29-34, pages 8-9, claims *;
 [X]WO2018144968  (ACCELERON PHARMA INC [US]) [X] 2, 13-26, 43-46 * Examples 3-8, in particular, the sequences disclosed in the Examples *;
 [A]WO2019086331  (BAYER AG [DE]) [A] 1-46* Abstract, Examples 2, 9-10 *;
 [X]WO2019117208  (KYOWA HAKKO KIRIN CO LTD [JP]) [X] 1-12,27-42;
 [X]  - Tu Ly, Desroches-Castan Agnès, Mallet Christine, Guyon Laurent, Cumont Amélie, Phan Carole, Robert Florian, Thuillet Raphaël, Bordenave Jennifer, Sekine Ayumi, Huertas Alice, Ritvos Olli, Savale Laurent, Feige Jean-Jacques, Humbert Marc, Bailly Sabine, Guignabert Christophe, "Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension", CIRCULATION RESEARCH, GRUNE AND STRATTON, US, (20190315), vol. 124, no. 6, doi:10.1161/CIRCRESAHA.118.313356, ISSN 0009-7330, pages 846 - 855, XP055834375 [X] 1-4, 15, 29-32 * . Abstract, pages 849-851, Figure 3C *

DOI:   http://dx.doi.org/10.1161/CIRCRESAHA.118.313356
 [X]  - Ayumi Sekine, Ly Tu, Christine Mallet, Jennifer Bordenave, Raphael Thuillet, Carole Phan, Paul-Benoit Poble, Alice Huertas, Marc Humbert, Sabine Bailly, Christophe Guignabert, "Contribution of BMP9 to Pulmonary Arterial Hypertension", European Respiratory Journal, (20170101), vol. 50, no. Suppl 61, doi:10.1183/1393003.congress-2017.OA4658, ISSN 0903-1936, page OA 4658, XP009529612 [X] 1-4, 15, 24-25 * .OA4658 The entire document *

DOI:   http://dx.doi.org/10.1183/1393003.congress-2017.OA4658
 [A]  - Nikolic Ivana, Yung Lai-Ming, Yang Peiran, Malhotra Rajeev, Paskin-Flerlage Samuel D., Dinter Teresa, Bocobo Geoffrey A., Tumelty Kathleen E., Faugno Anthony J., Troncone Luca, Mcneil Megan E., Huang Xiuli, Coser Kathryn R., Lai Carol S. C., Upton Paul D., Goumans Marie Jose, Zamanian Roham T., Elliott C. Gregory, Lee Arthur, Zheng Wei, Berasi Stephen P., Huard Christine, Morrell Nicholas W., Chung Raymond T., Channick Richard W., Roberts Kari E., Yu Paul B., "Bone Morphogenetic Protein 9 Is a Mechanistic Biomarker of Portopulmonary Hypertension", American Journal of Respiratory and Critical Care Medicine, US, (20190401), vol. 199, no. 7, doi:10.1164/rccm.201807-1236OC, ISSN 1073-449X, pages 891 - 902, XP055834433 [A] 1-46 * . Abstract, page 898, page 899 middle and right column, page 900 right column para. 1 *

DOI:   http://dx.doi.org/10.1164/rccm.201807-1236OC
 [A]  - Li, Wei; Salmon, Richard M.; Jiang, He; Morrell, Nicholas W., "Regulation of the ALK1 ligands, BMP9 and BMP10", Biochemical Society Transactions, (20160815), vol. 44, no. 4, doi:10.1042/BST20160083, ISSN 0300-5127, pages 1135 - 1141, XP009529617 [A] 1-46 * . page 1138 left column, page 1138 right column para. 1, page 1139 right column para. 3, page 1140 left column para. 1 *

DOI:   http://dx.doi.org/10.1042/BST20160083
 [A]  - Mark L. Ormiston, Paul D. Upton, Wei Li, Nicholas W. Morrell, "The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertension", GLOBAL CARDIOLOGY SCIENCE & PRACTICE 2013, (20150901), vol. 2015, no. 4, doi:10.5339/gcsp.2015.47, ISSN 2305-7823, page 47, XP055368628 [A] 1-46 * page 2 para. 3 until page 3 para. 4, page 6 para. 5 until page 8 para. 2 *

DOI:   http://dx.doi.org/10.5339/gcsp.2015.47
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.